Neogen Financial Statements
NASDAQ: NEOGHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Neogen revenue and earnings
In fiscal 2026, Neogen generated $870.4 million in revenue, down 2.7% from fiscal 2025, its first annual decline since 2025. Neogen reported a net loss of $7.9 million, compared with a loss of $1.09 billion a year earlier. Gross margin was 46.9% (down from 47.1%) and operating margin -2.5%.
Diluted earnings per share came in at -$0.04. Over the last 5 fiscal years, NEOG's revenue has grown at a 13.2% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
Neogen income statement (annual)
| Fiscal year (USD) | FY 20262026-05-31 | FY 20252025-05-31 | FY 20242024-05-31 | FY 20232023-05-31 | FY 20222022-05-31 | FY 20212021-05-31 | FY 20202020-05-31 | FY 20192019-05-31 | FY 20182018-05-31 | FY 20172017-05-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 870.40M | 894.70M | 924.20M | 822.45M | 527.16M | 468.46M | 418.17M | 414.19M | 397.93M | 358.28M |
| Revenue growth (YoY) | -2.72% | -3.19% | +12.37% | +56.01% | +12.53% | +12.03% | +0.96% | +4.09% | +11.07% | +11.52% |
| Cost of Revenue | 461.90M | 473.29M | 460.32M | 416.49M | 284.15M | 253.40M | 221.89M | 222.27M | 211.66M | 189.63M |
| Gross Profit | 408.50M | 421.40M | 463.90M | 405.95M | 243.01M | 215.06M | 196.28M | 191.92M | 186.27M | 168.92M |
| Operating Expenses | 430.10M | 1.48B | 405.30M | 368.44M | 184.40M | 140.89M | 128.76M | 123.83M | 116.08M | 103.98M |
| Research & Development | 18.40M | 21.10M | 22.50M | 26.04M | 17.05M | 16.25M | 14.75M | 12.80M | 10.86M | 10.38M |
| Selling, General & Admin | 411.70M | 402.00M | 382.80M | 342.40M | 167.35M | 124.64M | 114.01M | 111.02M | 105.22M | 93.59M |
| Operating Income | -21.60M | -1.06B | 58.60M | 37.52M | 58.62M | 74.17M | 67.52M | 68.09M | 70.19M | 64.94M |
| Interest Expense | 24.10M | 38.10M | 42.15M | 27.25M | — | — | — | — | — | — |
| Other Income (Expense) | 12.60M | -72.10M | -72.90M | -59.56M | 1.59M | 1.10M | 4.78M | 4.87M | 3.27M | 1.73M |
| Pretax Income | -9.00M | -1.13B | -14.30M | -22.04M | 60.21M | 75.27M | 72.31M | 72.96M | 73.47M | 66.67M |
| Income Tax | -1.10M | -41.10M | -4.90M | 828.00K | 11.90M | 14.39M | 12.83M | 12.78M | 10.25M | 22.70M |
| Net Income | -7.90M | -1.09B | -9.40M | -22.87M | 48.31M | 60.88M | 59.48M | 60.18M | 63.15M | 43.79M |
| Net Income growth (YoY) | — | — | — | -147.34% | -20.65% | +2.37% | -1.16% | -4.70% | +44.19% | +19.77% |
| EPS (Basic) | -0.04 | -5.03 | -0.04 | -0.12 | 0.45 | 0.57 | 0.57 | 0.58 | 1.23 | 0.87 |
| EPS (Diluted) | -0.04 | -5.03 | -0.04 | -0.12 | 0.45 | 0.57 | 0.56 | 0.57 | 1.21 | 0.86 |
| Shares Outstanding (Basic) | 217.50M | 216.90M | 216.50M | 188.88M | 107.68M | 106.50M | 105.10M | 103.78M | 51.36M | 50.54M |
| Shares Outstanding (Diluted) | 217.50M | 216.90M | 216.50M | 188.88M | 108.02M | 107.12M | 105.72M | 104.85M | 52.15M | 51.16M |
| EBITDA | 94.70M | -941.50M | 175.30M | 125.89M | 82.31M | 95.21M | 85.92M | 85.72M | 87.25M | 79.64M |
| Gross Margin | 46.93% | 47.10% | 50.19% | 49.36% | 46.10% | 45.91% | 46.94% | 46.34% | 46.81% | 47.15% |
| Operating Margin | -2.48% | -118.59% | 6.34% | 4.56% | 11.12% | 15.83% | 16.15% | 16.44% | 17.64% | 18.13% |
| Net Margin | -91.00% | -122.05% | -102.00% | -2.78% | 9.16% | 13.00% | 14.22% | 14.53% | 15.87% | 12.22% |
This table shows 10 annual periods of Neogen's income statement, from FY 2026 back to FY 2017, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow NEOG's reporting calendar. What is a income statement?